头颈癌管理的区域差异:世界耳鼻咽喉科学会联合会全球横断面调查
结果显示不同区域对早期口咽癌和晚期喉癌的管理选择差异显著(p<0.001),资源可及性与多学科肿瘤委员会审查比例亦存在广泛差异,经济障碍的分布因地区而异。
要点
- 早期口咽癌经口机器人手术(TORS)使用率北美59.1%、欧洲52.3%、亚洲14.8%、非洲7.1%。
- 晚期喉癌首选放化疗比例北美72.7%、亚洲43.5%、欧洲21.9%、非洲4.8%。
- 调强放疗(IMRT)可及率欧洲86.9%、中南美75.6%、非洲27.1%;经济障碍非洲83.7%、中南美63%、北美44.4%、欧洲8.9%。
核心结论
- 这项全球调查记录了头颈癌管理中的显著差异,反映了培训模式、资源环境和文化的复杂交互作用。
- 这些发现确认了标准化病例呈现中临床决策的区域差异,并确认需要制定资源调整的指南和国家特定的教育项目。
- 未来研究必须解决这些治疗模式如何影响不同医疗体系中的结局。
研究设计与样本
- 2024年9月至12月在世界耳鼻咽喉科学会联合会(IFOS)及其青年耳鼻咽喉科医生组织(YO-IFOS)主持下开展的横断面全球调查,遵循STROBE和CHERRIES指南。
- 调查采用标准化病例情景、实践环境特征和资源可及性评估,由七个地理区域的专业组织联系头颈疾病专家。
- 统计分析采用卡方检验和Benjamini-Hochberg校正进行多重比较。
- 回复者包括185名欧洲专家、27名北美专家、50名中南美专家、123名亚洲专家、53名非洲专家、12名大洋洲专家和114名中东/北非专家。
主要发现
- 标准化病例情景的管理因区域而异(p < 0.001)。
- 早期口咽癌的TORS率在各国之间差异显著:北美59.1%、欧洲52.3%、亚洲14.8%、非洲7.1%。
- 晚期喉癌的首选管理亦异质:北美72.7%选择首选放化疗,而亚洲仅43.5%、欧洲21.9%、非洲4.8%。
- IMRT等最先进治疗的可及性:欧洲86.9%、中南美75.6%、非洲27.1%。
- 所有患者均接受跨学科团队肿瘤委员会审查的比例:欧洲和大洋洲91.2%,亚洲48.8%,中南美22.4%。
关键数值与推荐
- 早期口咽癌TORS使用率:北美59.1%、欧洲52.3%、亚洲14.8%、非洲7.1%。
- 晚期喉癌首选放化疗比例:北美72.7%、亚洲43.5%、欧洲21.9%、非洲4.8%。
- IMRT可及率:欧洲86.9%、中南美75.6%、非洲27.1%。
- 所有患者跨学科肿瘤委员会审查率:欧洲和大洋洲91.2%、亚洲48.8%、中南美22.4%。
- 经济障碍报告率:非洲83.7%、中南美63%、北美44.4%、欧洲8.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To outline global variations in head and neck cancer care practices and resource availability across disparate geographic locations and sites of care. METHODS: We conducted a cross-sectional worldwide survey following STROBE and CHERRIES guidelines in September-December 2024 under the aegis of the World Federation of ENT Societies (IFOS) and Young Otolaryngologists of IFOS (YO-IFOS). The survey was conducted in the form of standardized case vignettes for common clinical scenarios for various head and neck subsites, practice setting characteristics, and resource availability assessment. Head and neck condition specialists were approached by professional organizations from seven geographic locations. Statistical analysis involved chi-square testing and Benjamini-Hochberg adjustment for multiple comparisons. RESULTS: One hundred eighty-five European specialists, 27 North American specialists, 50 Central/South American specialists, 123 Asian specialists, 53 African specialists, 12 Oceania specialists, and 114 Middle East/North African specialists responded to the survey. Management of standardized case vignettes was very different by region (p < 0.001). The rate of TORS for early oropharyngeal cancer differed significantly between nations (59.1% in North America, 52.3% in Europe, 14.8% in Asia, and 7.1% in Africa). Preferred management of advanced laryngeal cancer was also heterogeneous, with primary chemoradiotherapy being the option for 72.7% of North Americans but only 43.5% of Asians, 21.9% of Europeans, and 4.8% of Africans. Wide resource variations existed globally, with the most advanced treatment, such as IMRT, being available in 86.9% of European but only 75.6% of Central/South American and 27.1% of African centers. By contrast, tumor board review by an interdisciplinary team in all patients was noted in 91.2% of cases in Europe and Oceania compared with 48.8% in Asia and 22.4% in Central/South America. Economic barriers to access varied geographically and were noted in 83.7% of African, 63% of Central/South American, and 44.4% of North American, but just 8.9% of European respondents. CONCLUSIONS: This global survey documents notable variations in the management of head and neck cancer reflecting complex interactions between training models, resource settings, and cultural paradigms. These findings identify regional variations in clinical decision-making for standardized case presentations, confirming the need for resource-adjusted guideline development and country-specific education programs. Future research must tackle the way in which these patterns of treatment influence outcomes in diverse healthcare systems.
引用
- Maniaci A, Lechien JR, Chiesa-Estomba C, et al. Regional Disparities in Head and Neck Cancer Management: A Global Cross-Sectional Survey of the World Federation of ENT Societies. Head Neck. 2025. PMID: 40698453. doi:10.1002/hed.28257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。